Fairvalue-Calculator Fairvalue-Calculator
EN DE

Alfresa Holdings (ALFRY) Fair Value & Analysis

Healthcare · US · Market cap $2.4B

Price$13.80
Fair Value$13.46
Upside-2.5%
Quality95/100
Evidence: High Range $11.00 – $14.38

Analysis

Alfresa Holdings (ALFRY) currently trades at $13.80, while our model-based Fair Value estimate is $13.46 — implying the stock looks roughly 2.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is also involved in the operation of dispensing pharmacies and conducting related businesses; ethical pharmaceuticals wholesaling business; self-medication products wholesaling business; and other medical-related businesses. In addition, the company manufactures and markets active pharmaceutical ingredients; contract distribution services in hospitals; operation, maintenance, and development of information system; supply of cell raw materials; manufacturing of specific processed cells and regenerative medicine products. The company was incorporated in 2003 and is based in Tokyo, Japan.

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) -81% Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -38% Sigma Healthcare Limited (SIGGF) -67% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +183%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.